The aim is to compare the effect of two larger doses given three weeks apart with two smaller doses given on the same schedule, to see which approach better prevents a return to heavy drinking after a period of detoxification. Participants will receive the assigned capsules, attend regular check‑in visits, and record their drinking using a calendar method that helps recall daily alcohol use.

During the six‑month follow‑up, researchers will note the first day a participant drinks a large amount (defined as at least 60 g of alcohol) and will collect information on mood, anxiety, and overall quality of life at several points. Blood samples will also be taken at the start and near the end of the study to monitor safety.

The purpose of the study is to evaluate the long‑term outcomes and safety of repeated adjuvant (additional) treatment with rituximab in this condition. Participants receive two infusions several weeks apart and are then followed for several months with regular clinic visits to check how they feel and to monitor any side effects.

During the follow‑up, doctors use simple rating scales such as the Clinical Global Impression – Improvement, which measures how much a person’s symptoms have gotten better, and the Clinical Global Impression – Severity, which rates how serious the illness is. Patients also complete short questionnaires about their overall health, daily functioning, and any changes in blood tests that may show immune system activity. Family members may be asked to give their view of any improvement as well.

Participants will take the study drug by mouth every day for several months, with regular visits to check for any side effects and to answer simple questionnaires. Researchers will monitor for any new health problems, serious problems, and specific symptoms related to the study drugs. They will also use a few rating tools to watch for movement‑related side effects and to assess thoughts of self‑harm, using the C-SSRS questionnaire and movement scales called the SAS, BARS, and AIMS. The study ends after the treatment period and a short follow‑up to confirm the safety findings.

Table of Contents

• What is Tianeptine?
• Medical Conditions Treated with Tianeptine
• How Tianeptine Works
• Dosage and Administration
• Potential Side Effects
• Ongoing Research

What is Tianeptine?

Tianeptine is a unique antidepressant and anxiolytic (anti-anxiety) medication that has been used clinically in Europe, Asia, and South America since the late 1980s^[1]. It is known by various brand names, including Stablon (Servier) and Tianeurax^[2][1]. Unlike many other antidepressants available in the United States, tianeptine has a different mechanism of action, primarily affecting the brain’s opioid system^[1].

Medical Conditions Treated with Tianeptine

Tianeptine is used to treat several mental health and neurological conditions, including:

• Major Depressive Disorder (MDD): Tianeptine is primarily used as an antidepressant for treating MDD, especially in cases where other antidepressants have not been effective^[1][3].
• Bipolar Depression: Some studies are investigating the use of tianeptine as an adjunctive (add-on) therapy for bipolar depression^[2].
• Anxiety Disorders: Tianeptine has anxiolytic properties, making it potentially useful for treating anxiety^[2].
• Post-Mastectomy Pain Syndrome (PMPS): Research is being conducted on tianeptine’s effectiveness in treating chronic pain after breast cancer surgery^[4].
• COVID-19 Related Cognitive Impairment (“Covid Fog”): Ongoing studies are exploring tianeptine’s potential in treating cognitive symptoms experienced by some COVID-19 survivors^[5].

How Tianeptine Works

Tianeptine’s mechanism of action is unique compared to other antidepressants. Here’s what we know about how it works:

• Opioid System Interaction: Tianeptine acts as a selective agonist of the mu-opioid receptor (MOR), which is similar to how the body’s natural pain-relieving chemicals (endorphins) work^[1].
• Neurotransmitter Modulation: It affects various neurotransmitters in the brain, including serotonin, dopamine, and glutamate^[2].
• Neuroprotection: Tianeptine may have neuroprotective effects, potentially helping to prevent cellular damage in the brain^[2].
• Stress Response Reduction: It can reduce the body’s stress response, which may help with stress-related behavioral issues^[2].

Dosage and Administration

The dosage of tianeptine can vary depending on the condition being treated and the patient’s age. Here are some general guidelines based on the clinical trials:

• For depression and anxiety: 12.5 mg taken three times daily^[2][6].
• For older patients (over 70 years): 12.5 mg taken twice daily^[5].
• For post-mastectomy pain: 12.5 mg taken three times daily^[4].

It’s important to note that tianeptine should only be taken under the supervision of a healthcare professional, as dosages may need to be adjusted based on individual response and side effects.

Potential Side Effects

While tianeptine is generally well-tolerated, it can cause side effects. Some potential side effects include:

• Nausea and vomiting
• Constipation
• Dizziness
• Drowsiness or sedation
• Headache
• Dry mouth

As with any medication, it’s important to discuss potential side effects with your healthcare provider^[3].

Ongoing Research

Tianeptine is currently being studied for various conditions and potential applications:

• Treatment-Resistant Depression: Research is ongoing to determine if tianeptine can be effective for patients who haven’t responded to other antidepressants^[1].
• Cognitive Function in Autism Spectrum Disorder (ASD): Studies are investigating how tianeptine affects brain function in individuals with ASD^[7].
• Post-COVID Cognitive Impairment: Researchers are exploring tianeptine’s potential in treating cognitive symptoms experienced by some COVID-19 survivors, often referred to as “Covid fog”^[5].
• Chronic Pain Management: Tianeptine’s unique mechanism of action is being studied for its potential in managing chronic pain conditions^[4].

As research continues, our understanding of tianeptine’s potential benefits and risks may evolve. It’s important for patients to stay informed and consult with their healthcare providers about the latest developments in tianeptine research and its potential applications for their specific conditions.

Table of Contents

• Trial overview
• Study design and treatment groups
• Who participated
• What the trial measured
• Why this study matters

Trial overview

The trial titled Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine studied people with depression.^[1] It was an interventional Phase 3 study with 100 enrolled participants and a completed status.^[1]

The study looked at two goals: reducing cognitive side-effects after ECT and improving the ability to predict who would respond to ECT.^[1] ECT means electroconvulsive therapy, a treatment used in severe depression.^[1]

Study design and treatment groups

The trial compared RIVASTIGMINE with placebo using transdermal use, which means the treatment was given through the skin with an adhesive plaster.^[1] The source lists two active doses, 9.5 mg and 4.6 mg, and matching placebo plasters that contained 0 mg of rivastigmin.^[1]

This design helped researchers compare changes in thinking and memory between the RIVASTIGMINE group and the placebo group.^[1]

Who participated

The target population was people with depression.^[1] The source does not provide more detailed entry rules, such as age limits, severity rules, or other medical conditions required for participation.

Because the study focused on ECT, the participants were people for whom ECT was being considered or used as part of care in the research setting.^[1]

What the trial measured

The main outcome was whether there was no change in the RIVASTIGMINE group on cognitive and memory-related measures, compared with an effect in the placebo group.^[1] In simple terms, the researchers wanted to see if RIVASTIGMINE could prevent or reduce worsening in thinking and memory after ECT.^[1]

The trial also measured whether a classification algorithm could accurately predict ECT response and side-effects at a statistically significant level.^[1] A classification algorithm is a rule-based or computer-based method that sorts people into groups, such as likely responder or non-responder.^[1]

Another part of the study used EEG, which is a test that records brain activity, to help build the prediction method for ECT response.^[1]

Why this study matters

The study aimed to improve the acceptability and tolerability of ECT by reducing its cognitive side-effects.^[1] Better memory and thinking outcomes could make ECT easier to use for people with chronic severe depression.^[1]

The researchers also wanted to avoid giving ECT to people who are unlikely to benefit, because this could expose them to risks without enough chance of improvement.^[1] In this way, the trial combined a treatment question with a prediction question: can RIVASTIGMINE help after ECT, and can EEG plus clinical data better forecast ECT results?^[1]

Table of Contents

• What is Pipotiazine?
• Medical Uses
• Treatment Strategies
• Patient Monitoring
• Cycloid Psychosis vs. Non-Cycloid Psychosis
• Considerations for Patients

What is Pipotiazine?

Pipotiazine (also known as Pipotiazine palmitate) is a first-generation antipsychotic medication. It belongs to a group of medications called “typical antipsychotics” or “conventional antipsychotics.” These are older medications developed to treat various mental health conditions, particularly those involving psychosis.^[1] First-generation antipsychotics like Pipotiazine work primarily by blocking dopamine receptors in the brain, which helps control symptoms of psychosis.

Medical Uses

Pipotiazine is primarily used to treat disorders within the schizophrenia spectrum. Based on the clinical trial information, these disorders include:^[1]

• Schizophrenia – A serious mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior
• Schizophreniform disorder – Similar to schizophrenia but lasting less than six months
• Schizoaffective disorder – A condition where a person experiences a combination of schizophrenia symptoms and mood disorder symptoms
• Brief psychotic episodes – Short periods of psychotic behavior often triggered by extreme stress

The medication helps manage symptoms such as hallucinations, delusions, disorganized thinking, and other psychotic symptoms that characterize these conditions.^[1]

Treatment Strategies

According to the clinical trial data, there are two main treatment strategies being studied with Pipotiazine and other antipsychotics:^[1]

1. Dose Reduction Strategy – This involves gradually reducing the patient’s usual antipsychotic dose to levels lower than those typically recommended by official guidelines. This strategy is being explored as many patients express a desire to reduce or stop their antipsychotic medication once they achieve clinical stability.
2. Maintenance Treatment Strategy – This involves maintaining the patient’s antipsychotic dose in accordance with the officially recommended dosages.

The clinical trial is specifically investigating whether different types of patients (based on their psychotic phenotype – which means the observable characteristics of their illness) might respond differently to these two strategies.^[1]

Patient Monitoring

When taking Pipotiazine, patients in the clinical trial undergo regular monitoring to assess their progress and ensure their safety:^[1]

• Regular follow-up visits (monthly for four months, then every two months)
• Completion of self-questionnaires and cognitive tests by the patient and their caregiver
• Blood samples taken at specific intervals to measure medication levels in the blood
• Assessment of functional remission using the Personal and Social Performance Scale (a tool that measures how well a person is functioning in their daily life)

This comprehensive monitoring helps healthcare providers track how well the medication is working and whether any adjustments are needed to the treatment plan.^[1]

Cycloid Psychosis vs. Non-Cycloid Psychosis

The clinical trial is exploring whether patients with different types of psychosis respond differently to dose reduction versus maintenance treatment. The two types being studied are:^[1]

• Cycloid Psychosis (CP) – This is a form of psychosis characterized by sudden onset, rapidly changing symptoms, and often good recovery between episodes. Symptoms can include confusion, mood changes, and hallucinations that come and go in a cyclical pattern.
• Non-Cycloid Psychosis (Non-CP) – This refers to other forms of psychosis that don’t follow the cyclical pattern seen in cycloid psychosis.

The research hypothesis is that patients with cycloid psychosis might benefit more from dose reduction compared to those with non-cycloid psychosis.^[1]

Considerations for Patients

If you are taking Pipotiazine or another antipsychotic medication and are interested in potentially reducing your dose, there are several important points to consider:^[1]

• Never adjust your medication without medical supervision – The clinical trial emphasizes the importance of proper medical guidance when reducing antipsychotic doses
• Individual response varies – The study is specifically looking at how different types of patients respond to dose reduction, suggesting that what works for one person may not work for another
• Regular monitoring is essential – Frequent follow-ups with healthcare providers help ensure that any changes in symptoms are detected early
• Blood tests may be needed – To accurately assess medication levels and effectiveness
• Support from caregivers is valuable – The study involves input from caregivers, highlighting their important role in the treatment process

The clinical trial acknowledges that many patients wish to reduce their antipsychotic medication once they’ve achieved stability, but also notes that psychiatrists have been reluctant to do so because “the method for safely reducing or stopping antipsychotic treatment remains poorly understood.” This research aims to provide better guidance on this important question.^[1]

Table of Contents

• What is Paroxetine?
• What Conditions Does Paroxetine Treat?
• How Does Paroxetine Work?
• Dosage Forms and Strengths
• Effectiveness of Paroxetine
• Potential Side Effects
• Use in Special Populations
• Drug Interactions

What is Paroxetine?

Paroxetine is a medication that belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs). It is widely used to treat various mental health conditions and other disorders. Paroxetine is known by several brand names, including Paxil, Paxil CR (controlled release), and Brisdelle^[1][2]. In some studies, it is also referred to as paroxetine mesylate or LDMP (Low-Dose Mesylate salt of Paroxetine)^[10].

What Conditions Does Paroxetine Treat?

Paroxetine is used to treat several mental health conditions and other disorders, including:

• Anxiety Disorders: Paroxetine is effective in treating various forms of anxiety, including social anxiety disorder (social phobia)^[1][5].
• Depression: It is commonly prescribed for major depressive disorder^[3].
• Panic Disorder: Paroxetine has shown efficacy in treating panic attacks and panic disorder^[4].
• Vasomotor Symptoms of Menopause: A low-dose formulation of paroxetine (Brisdelle) is used to treat hot flashes and night sweats associated with menopause^[10][11].

How Does Paroxetine Work?

Paroxetine works by increasing the levels of a neurotransmitter called serotonin in the brain. Serotonin is a chemical messenger that plays a crucial role in regulating mood, anxiety, and other mental states. By blocking the reuptake (reabsorption) of serotonin, paroxetine allows more serotonin to remain available in the brain, which can help improve mood and reduce anxiety symptoms^[4].

Dosage Forms and Strengths

Paroxetine is available in several forms and strengths:

• Immediate-release tablets: Usually available in strengths of 20 mg, 30 mg, and 40 mg^[1].
• Controlled-release tablets (Paxil CR): Available in 37.5 mg strength^[3].
• Low-dose capsules (Brisdelle): Available as 7.5 mg capsules for treating menopausal symptoms^[10][11].

The dosage and form prescribed will depend on the condition being treated and individual patient factors. It’s important to take paroxetine exactly as prescribed by your healthcare provider.

Effectiveness of Paroxetine

Clinical trials have demonstrated the effectiveness of paroxetine in treating various conditions:

• Anxiety and Depression: Studies have shown that paroxetine can significantly improve symptoms of anxiety and depression compared to placebo^[5].
• Panic Disorder: Research indicates that paroxetine can reduce the frequency and severity of panic attacks^[4].
• Menopausal Symptoms: Low-dose paroxetine (Brisdelle) has been found to reduce the frequency and severity of hot flashes in postmenopausal women^[10][11].

The effectiveness of paroxetine may vary from person to person, and it may take several weeks to experience the full benefits of the medication.

Potential Side Effects

Like all medications, paroxetine can cause side effects. Common side effects may include:

• Nausea
• Drowsiness
• Dry mouth
• Insomnia
• Sexual dysfunction
• Changes in appetite or weight

Most side effects are mild and tend to improve over time. However, if you experience any severe or persistent side effects, it’s important to contact your healthcare provider^[1][10].

Use in Special Populations

Paroxetine should be used with caution in certain populations:

• Pregnant Women: The use of paroxetine during pregnancy should be carefully considered due to potential risks to the fetus.
• Elderly Patients: Lower doses may be recommended for older adults to reduce the risk of side effects.
• Patients with Liver or Kidney Disease: Dose adjustments may be necessary for individuals with impaired liver or kidney function.

Always inform your healthcare provider about your complete medical history and any other medications you are taking before starting paroxetine^[10][11].

Drug Interactions

Paroxetine can interact with various medications and substances. Some important interactions to be aware of include:

• Other antidepressants, particularly monoamine oxidase inhibitors (MAOIs)
• Certain pain medications
• Blood thinners
• Some migraine medications
• Alcohol

It’s crucial to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions^[1][10].

Table of Contents

• What OMEGA-3-ACID ETHYL ESTERS 90 is (and names used in trials)
• How the drug was studied (trial designs and comparisons)
• Trials in hypertriglyceridemia (high triglycerides)
• Trial in HIV patients on HAART: cardiovascular risk factors
• Trial in chronic hemodialysis: preventing cardiovascular events
• Trial in early psychosis: Omacor as part of personalised care
• Safety monitoring used across trials
• What outcomes and tests were used (plain-language guide)

What OMEGA-3-ACID ETHYL ESTERS 90 is (and names used in trials)

OMEGA-3-ACID ETHYL ESTERS 90 is an omega‑3 fatty acid medicine tested in multiple clinical trials. In the provided trial data, it appears under several names, including Omacor, LOVAZA, and TAK-085.

In the hypertriglyceridemia trials that used the name TAK-085, the capsule content is described as omega‑3 fatty acid ethyl esters mainly made of ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoic acid (DHA-E).

Some trials specifically refer to Omega-3-Acid Ethyl Esters 90 Soft Capsules (1 g soft gel capsules), taken as four capsules once daily with breakfast for 12 weeks.

^[1][2][3][4]

How the drug was studied (trial designs and comparisons)

Across the provided studies, researchers used different trial designs to compare omega‑3 treatment with other options.

• Randomized designs: participants were assigned by chance to different study groups. This helps make the comparison fairer.

• Double-blind studies: neither participants nor study staff knew which treatment was given during the study. This reduces bias when judging outcomes.

• Open-label study: the long-term hypertriglyceridemia study was open-label, meaning treatment was known.

• Different comparators were used, including placebo, corn oil control capsules, and an active comparator, ethyl eicosapentaenoate (EPA-E).

The treatment duration also varied widely, from 12 weeks in several trials to 52 weeks in a long-term hypertriglyceridemia study, and 2 years in a hemodialysis study.

^[2][1][3][5]

Trials in hypertriglyceridemia (high triglycerides)

Several trials focused on hypertriglyceridemia, meaning high triglycerides in the blood.

Key ways these trials measured benefit were based on how much fasting triglycerides changed from baseline (the start of treatment) to later study visits.

• Phase 3, double-blind 12-week study (TAK-085): This study compared TAK-085 2 g once daily or 2 g twice daily with EPA-E 0.6 g three times daily. The main outcome was the percent change from baseline in triglyceride level at the final visit. The study also followed cholesterol measures over time (LDL-C, HDL-C, total cholesterol, and non-HDL-C) and tracked treatment-emergent side effects.

• Phase 3, open-label long-term study (TAK-085, 52 weeks): This study primarily focused on safety over 52 weeks, counting participants with treatment-emergent adverse events (TEAEs), including those linked with abnormal vital signs, body weight changes, ECG findings, and lab test abnormalities (chemistry, hematology, urinalysis). It also measured lipid changes such as triglycerides and cholesterol values at multiple time points through week 52.

• Phase 3, double-blind corn oil-controlled study (12 weeks) in severe hypertriglyceridemia: This study enrolled people with fasting triglycerides at or above 500 mg/dL and below 2000 mg/dL. Participants took four 1 g soft capsules once daily with breakfast for 12 weeks. The primary outcome was end-of-treatment fasting triglycerides percent change from baseline. Secondary outcomes included non-HDL-C, total cholesterol, VLDL-C, HDL-C, LDL-C, the LDL-C/HDL-C ratio, and apolipoproteins (Apo A5 and Apo C3).

^[2][1][3]

Trial in HIV patients on HAART: cardiovascular risk factors

One trial studied Omacor (omega‑3‑acid ethyl ester 90) in people living with Human Immunodeficiency Virus (HIV) who were receiving HAART (Highly Active Antiviral Therapy).

The trial rationale described that more incidents of Ischemic Heart Disease (IHD) had been seen among patients on HAART. The trial discussion highlighted several possible contributors, including effects of HIV on the immune system, higher rates of risk behaviors (like smoking), and HAART-related increases in cholesterol and triglycerides linked with HIV-related lipodystrophy (metabolic and body-fat changes).

Design details in the provided data included about 50 participants randomized to Omacor 4 g/day or placebo for 12 weeks.

• Primary outcome: change in plasma triglycerides from baseline to week 12.

• Secondary outcomes: blood vessel stiffness and function measured by pulse wave velocity and flow mediated vasodilation; cholesterol measures (HDL, LDL, total cholesterol); inflammatory and vascular-related blood markers such as ICAM, VCAM, sensitive CRP; and multiple other laboratory markers listed in the trial, plus safety parameters.

^[4]

Trial in chronic hemodialysis: preventing cardiovascular events

Another study tested OMACOR in people with chronic kidney failure who were undergoing chronic hemodialysis and had previously experienced a cardiovascular event.

This was described as a prospective, randomized, placebo-controlled study with a 2-year treatment period. The main goal was to see whether OMACOR affected the incidence of cardiovascular events and mortality in this high-risk group.

The primary outcome was a composite endpoint, meaning the study counted whether a participant had any of several serious events, including:

• Acute myocardial infarction (heart attack)

• Angina pectoris leading to coronary investigation or intervention

• Transient cerebral ischemia (TCI)

• Apoplexia cerebri (stroke)

• Peripheral vascular disease with new or worsening symptoms

Secondary outcomes included lab measures (lipids and other markers, including adhesion molecules and an LDL-related size variable), fatty acid profiles in phospholipids, diet registration and “fish score,” thrombosis/stenosis of dialysis graft, and a substudy on heart rate variability (baseline and after three months) in 50 patients.

^[5]

Trial in early psychosis: Omacor as part of personalised care

One trial record from a European registry described Omacor 1000 mg soft capsules (active substance omega‑3‑acid ethyl esters 90) as part of a broader “composite personalised care” approach in adolescents and young adults (15 to 30 years) who were Ultra High Risk of psychosis or experiencing a First Episode Psychosis in the first year after diagnosis and care.

The design was described as a phase III prospective randomized open, blinded end-point (PROBE) trial. The main objective was to compare different personalised-care strategies against treatment as usual on global functioning measured by the Personal and Social Performance (PSP) Scale over about 3 to 4 months after the beginning (as described in the record).

^[6]

Safety monitoring used across trials

Safety was tracked in multiple ways across the provided trials, especially in the hypertriglyceridemia studies.

• Treatment-emergent adverse events (TEAEs): how many participants had side effects or new medical issues after starting the study drug.

• Vital signs: trials counted TEAEs linked with abnormal vital sign changes.

• Body weight: one long-term study counted TEAEs associated with abnormal body weight changes.

• Electrocardiogram (ECG): trials tracked clinically significant abnormal ECG findings after taking the study drug.

• Laboratory tests: some trials grouped abnormal lab findings (chemistry, hematology, urinalysis) as safety-related TEAEs.

^[1][2]

What outcomes and tests were used (plain-language guide)

The provided trials used several types of measurements. Understanding these can help you follow what researchers were trying to learn.

• Fasting triglycerides: triglycerides measured after not eating for a period of time. Trials often reported the percent change from baseline to show improvement or worsening.

• Cholesterol panel measures: LDL-C (“bad cholesterol”), HDL-C (“good cholesterol”), total cholesterol, and non-HDL-C (total cholesterol minus HDL-C). Some trials also measured VLDL-C.

• Blood vessel tests: pulse wave velocity (artery stiffness) and flow mediated vasodilation (how well a vessel widens in response to blood flow, related to endothelial function).

• Composite cardiovascular endpoint: a combined outcome that counts if any serious cardiovascular event happens (for example heart attack, stroke, or angina requiring testing/procedures).

• Functioning scales in psychiatry: the PSP Scale measures day-to-day personal and social functioning in early psychosis research.

^[4][3][5][6]

Table of Contents

• What is Methadone?
• Uses of Methadone
• How Methadone is Administered
• Effects and Benefits
• Potential Side Effects
• Genetic Factors Affecting Methadone Metabolism
• Ongoing Research

What is Methadone?

Methadone hydrochloride, also known simply as methadone, is a powerful opioid medication. It’s similar to morphine in its pain-relieving properties but has some unique characteristics that make it useful for various medical purposes^[1]. Other names for methadone include Dolophine and Eptadone^[2][3].

Uses of Methadone

Methadone is primarily used for:

• Pain Management: It’s effective for treating moderate to severe pain, especially after surgery or in patients with chronic pain conditions^[1].
• Opioid Addiction Treatment: Methadone is used to help reduce withdrawal symptoms in people trying to quit other opioids^[4].

How Methadone is Administered

Methadone can be given in several ways:

• Intravenous (IV): Injected directly into a vein, often during surgery or immediately after for pain control^[1].
• Oral: Taken by mouth as a liquid or pill^[5].

The dosage of methadone can vary depending on the patient’s weight and the purpose of treatment. For example, in some studies, doses ranged from 0.1 mg/kg to 0.4 mg/kg of body weight^[6][2].

Effects and Benefits

Methadone has several potential benefits:

• Long-lasting pain relief: Unlike some other opioids, methadone can provide pain relief for an extended period, often up to 24-36 hours after a single dose^[1].
• Reduced opioid consumption: Some studies suggest that using methadone during surgery may lead to less need for other pain medications afterward^[1][6].
• Faster onset of action: Methadone starts working more quickly than some other opioids like morphine^[1].

Potential Side Effects

Like all medications, methadone can cause side effects. Some potential side effects include:

• Nausea and vomiting^[6]
• Constipation^[6]
• Drowsiness^[6]
• Respiratory depression: This means slowed breathing, which can be dangerous and may require an antidote in severe cases^[6].

It’s important to note that when used as prescribed under medical supervision, many of these side effects can be managed or minimized.

Genetic Factors Affecting Methadone Metabolism

Research has shown that genetic factors can influence how a person’s body processes methadone. Specifically, variations in a gene called CYP2B6 can affect how quickly the body breaks down methadone. This could impact how long the drug stays in the body and its effectiveness^[5].

Ongoing Research

Scientists are continually studying methadone to better understand its effects and find new ways to use it safely and effectively. Some areas of current research include:

• Use in specific surgeries: Studies are looking at how methadone might help with pain control after surgeries like spinal fusion or hip fracture repair^[2][6].
• Combination with other medications: Researchers are investigating whether combining methadone with other drugs like ketamine might provide better pain relief with fewer side effects^[4].
• Long-term effects: Studies are examining the impact of methadone use on long-term outcomes like quality of life and mobility after surgery^[6].

Table of Contents

• What is Florbetapir (18F)?
• How Does Florbetapir (18F) Work?
• Uses of Florbetapir (18F)
• How is Florbetapir (18F) Administered?
• Research Studies Using Florbetapir (18F)
• Safety and Side Effects

What is Florbetapir (18F)?

Florbetapir (18F) is a diagnostic drug used in medical imaging. It’s also known by several other names, including Florbetapir F 18, Amyvid, 18F-AV-45, and AV-45^[1][2]. This drug is not a treatment for Alzheimer’s disease, but rather a tool to help doctors diagnose the condition more accurately.

How Does Florbetapir (18F) Work?

Florbetapir (18F) works by binding to amyloid plaques in the brain. Amyloid plaques are abnormal clusters of protein that build up between nerve cells and are believed to play a role in Alzheimer’s disease. When Florbetapir (18F) is injected into the body, it travels to the brain and attaches to these plaques. Then, using a special type of scan called a Positron Emission Tomography (PET) scan, doctors can see where the Florbetapir (18F) has accumulated, showing them the location and amount of amyloid plaques in the brain^[1].

Uses of Florbetapir (18F)

The primary use of Florbetapir (18F) is to help diagnose Alzheimer’s disease and related cognitive disorders. It’s particularly useful in the following situations:

• Early detection: Florbetapir (18F) can help identify people who might be at risk for developing Alzheimer’s disease before they show any symptoms^[2].
• Differential diagnosis: It can help doctors distinguish Alzheimer’s disease from other types of dementia^[3].
• Research: Florbetapir (18F) is used in studies to better understand how Alzheimer’s disease progresses and to evaluate potential new treatments^[3].

How is Florbetapir (18F) Administered?

Florbetapir (18F) is given as a single intravenous (IV) injection. The typical dose is about 370 megabecquerels (MBq) or 10 millicuries (mCi)^[4]. After the injection, patients typically wait about 50-60 minutes before undergoing a PET scan that lasts about 10 minutes^[2]. It’s important to note that patients don’t receive Florbetapir (18F) as a regular medication, but only as part of a specific diagnostic procedure.

Research Studies Using Florbetapir (18F)

Several research studies have been conducted to evaluate the effectiveness and applications of Florbetapir (18F). Some key areas of research include:

• Improving diagnostic accuracy: Studies have looked at how Florbetapir (18F) PET scans can improve the accuracy of Alzheimer’s disease diagnosis^[1].
• Impact on patient management: Research has examined how the results of Florbetapir (18F) scans influence doctors’ decisions about patient care^[2].
• Predicting cognitive decline: Studies have investigated whether Florbetapir (18F) scan results can predict future cognitive decline in patients^[2].
• Standardization of measurements: Researchers have worked on standardizing how Florbetapir (18F) scan results are measured and interpreted across different medical centers^[5].

Safety and Side Effects

Florbetapir (18F) is generally considered safe when used as directed. As with any medical procedure involving radiation, there is a small risk associated with the exposure. However, the amount of radiation used in a Florbetapir (18F) PET scan is relatively low^[4].

It’s important to note that a Florbetapir (18F) scan is a diagnostic tool, not a treatment. A positive scan result doesn’t necessarily mean a person has Alzheimer’s disease, and a negative result doesn’t rule it out completely. The scan results should always be interpreted by a trained healthcare professional in conjunction with other clinical information.

Table of Contents

• What is Esketamine Hydrochloride?
• Medical Uses of Esketamine
• How is Esketamine Administered?
• Effects of Esketamine
• Potential Side Effects
• Ongoing Research

What is Esketamine Hydrochloride?

Esketamine hydrochloride, also known as Ketanest S or simply esketamine, is a medication that belongs to a class of drugs called dissociative anesthetics^[1]. It is derived from ketamine and is considered to be more potent and have fewer side effects than its parent compound^[2]. Esketamine works by affecting various receptors in the brain, particularly those involved in pain perception, mood regulation, and consciousness^[3].

Medical Uses of Esketamine

Esketamine has several medical applications, including:

• Treatment-resistant depression: Esketamine has been approved for use in patients with depression that hasn’t responded to other treatments^[4].
• Anesthesia: It is used as an anesthetic agent, particularly in situations where maintaining stable blood pressure is important^[5].
• Pain management: Esketamine is being studied for its potential in managing various types of pain, including chronic pain and pain associated with surgery^[6].
• Rett Syndrome: Research is being conducted to evaluate its effectiveness in treating symptoms of Rett Syndrome, a rare genetic neurological disorder^[7].
• Sepsis: Studies are exploring its potential anti-inflammatory effects in patients with sepsis, a life-threatening condition caused by the body’s response to infection^[8].

How is Esketamine Administered?

Esketamine can be administered in several ways, depending on the medical condition being treated and the specific clinical situation:

• Intravenous (IV) infusion: This is common in hospital settings, especially for anesthesia or pain management. The dose and duration can vary based on the patient’s needs^[9].
• Nasal spray: For treatment-resistant depression, esketamine may be given as a nasal spray under medical supervision^[10].
• Intramuscular injection: In some cases, esketamine might be injected into a muscle^[11].

Effects of Esketamine

Esketamine can have various effects on the body and mind, including:

• Rapid antidepressant action: Unlike traditional antidepressants that may take weeks to work, esketamine can provide relief from depressive symptoms much more quickly^[12].
• Pain relief: It has strong analgesic (pain-relieving) properties^[13].
• Cardiovascular stability: Esketamine can help maintain stable blood pressure during surgery, which is beneficial for certain patients^[14].
• Anti-inflammatory effects: Research suggests it may have anti-inflammatory properties, which could be beneficial in conditions like sepsis^[15].
• Dissociative effects: Patients may experience a feeling of detachment from their surroundings or themselves. This is usually temporary^[16].

Potential Side Effects

Like all medications, esketamine can cause side effects. Some potential side effects include:

• Nausea and vomiting^[17]
• Dizziness^[18]
• Changes in perception (feeling disconnected from your body or surroundings)^[19]
• Increased blood pressure^[20]
• Drowsiness^[21]

It’s important to note that when used under medical supervision, many of these side effects can be managed effectively.

Ongoing Research

Esketamine is the subject of ongoing research in various areas:

• Rett Syndrome: A study is investigating whether esketamine can improve symptoms in children with Rett Syndrome, a rare genetic disorder affecting brain development^[22].
• Sepsis: Researchers are exploring whether esketamine can reduce excessive inflammation and improve immune function in patients with sepsis^[23].
• Postoperative behavior in children: A study is examining if esketamine can reduce negative behavior changes in children after surgery^[24].
• Cancer-related pain and mood disorders: Research is being conducted on the effects of esketamine on postoperative pain, anxiety, and depression in cancer patients undergoing surgery^[25].
• Brain network function: Scientists are using brain imaging techniques to understand how esketamine affects brain networks, which could provide insights into its mechanism of action in conditions like schizophrenia^[26].

These ongoing studies aim to expand our understanding of esketamine’s potential benefits and risks in various medical conditions.

Table of Contents

• What is Choline Alfoscerate?
• How Choline Alfoscerate Works
• Medical Conditions Treated with Choline Alfoscerate
• Vascular Cognitive Impairment
• Post-Stroke Cognitive Recovery
• Depression with Memory Complaints
• Dosage Information
• Clinical Evidence and Effectiveness
• Side Effects and Safety

What is Choline Alfoscerate?

Choline alfoscerate, also known as alpha-glyceryl phosphoryl choline or alpha-GPC, is a medication used to treat various cognitive disorders. It is marketed under several brand names including Gliatilin® and Delecit^[1][2]. This compound serves as a cholinergic precursor, which means it helps the body produce acetylcholine, an important neurotransmitter (chemical messenger) in the brain that plays a key role in memory and cognitive function.

How Choline Alfoscerate Works

Choline alfoscerate works by providing a source of choline to the brain. When it enters the body, it crosses the blood-brain barrier (a protective boundary that prevents many substances from reaching the brain) and is converted into acetylcholine. This neurotransmitter is crucial for proper communication between nerve cells and plays a significant role in memory, attention, and cognitive functions^[1].

Research indicates that patients with certain cognitive disorders, including vascular cognitive impairment (cognitive problems related to blood vessel disease in the brain), often have deficits in brain cholinergic neurotransmission^[2]. By increasing the availability of acetylcholine, choline alfoscerate aims to improve these cognitive functions.

Medical Conditions Treated with Choline Alfoscerate

According to the clinical trials reviewed, choline alfoscerate is primarily investigated for treating several neurological and psychiatric conditions^[1][2][3][4]:

• Vascular Cognitive Impairment (VCI) – A spectrum of cognitive disorders related to cerebrovascular diseases
• Post-stroke cognitive deficits – Cognitive problems that occur after a stroke
• Major Depression with subjective memory complaints – In older adults who experience both depression and memory issues

Vascular Cognitive Impairment

Vascular Cognitive Impairment (VCI) encompasses a range of cognitive disorders related to blood vessel diseases in the brain. It can range from mild cognitive impairment to more severe dementia. Currently, there are no approved treatments specifically for VCI, and the main therapeutic approaches focus on controlling vascular risk factors to prevent development or progression^[2].

Several studies have found cholinergic deficits (problems with the acetylcholine system) in the brains of patients with VCI. Choline alfoscerate is being studied for its potential to address these deficits and improve cognitive function in these patients^[1].

One clinical trial is investigating whether a combination of choline alfoscerate (1200mg per day) and nimodipine (a calcium channel blocker that affects blood vessels) is more effective than nimodipine alone in reducing cognitive decline in patients with subcortical VCI^[2]. This approach targets both the cholinergic deficit and the vascular component of the disease.

Post-Stroke Cognitive Recovery

Stroke can cause significant cognitive impairment, affecting a person’s memory, attention, and other cognitive functions. Research suggests that choline alfoscerate may help improve cognitive function in post-stroke patients^[1][4].

One study is examining the effectiveness of choline alfoscerate compared to placebo in improving cognition in post-stroke patients with Vascular Cognitive Impairment-No Dementia (VCI-ND). This condition refers to cognitive problems related to vascular issues that are not severe enough to be classified as dementia^[1].

Another clinical trial is using Navigated Brain Stimulation (NBS) to evaluate the effect of different neuroprotective drugs, including choline alfoscerate, on motor centers and tracts after ischemic stroke. This approach allows researchers to measure the electrical activity in the brain more precisely than traditional clinical scales, potentially offering a more sensitive way to detect improvements^[4].

Depression with Memory Complaints

Older adults with Major Depressive Disorder (MDD) often experience subjective memory complaints, which can significantly impact their quality of life. A clinical trial is investigating whether choline alfoscerate can improve symptoms related to depression, anxiety, and subjective memory complaints in patients over the age of 60 who have MDD and subjective cognitive decline^[3].

In this study, participants receive choline alfoscerate as an adjunctive therapy (added to their regular antidepressant medication). The researchers are evaluating improvements in memory function, depression, anxiety, and satisfaction with medication over an 8-week period^[3].

Dosage Information

Based on the clinical trials reviewed, choline alfoscerate is administered in various dosages depending on the condition being treated^[1][2][3][4]:

• For Vascular Cognitive Impairment: 400mg three times a day (1200mg total daily dose) for 12 weeks^[1] or 600mg twice daily (1200mg total) in combination with nimodipine^[2]
• For Depression with Memory Complaints: 400mg twice daily^[3]
• For Post-Stroke Recovery: 1000mg daily intravenously (IV) for 10 days^[4]

The medication may be administered orally (by mouth) as tablets or intravenously, depending on the specific treatment protocol and the patient’s condition^[4].

Clinical Evidence and Effectiveness

Several clinical studies have investigated the effects of choline alfoscerate on cognitive function. According to one review mentioned in the trial information, a comparison of the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) results showed a more positive trend with choline alfoscerate than with certain cholinesterase inhibitors (another class of drugs used for cognitive disorders)^[1].

The effectiveness of choline alfoscerate is being measured using various assessment tools in the clinical trials, including^[1][2][3]:

• Korean Trail Making Test (K-TMT-e) – Assesses visual attention and task switching
• Montreal Cognitive Assessment (MoCA) – A rapid screening instrument for mild cognitive dysfunction
• Color Word Stroop Test (CWST) – Measures selective attention
• Trail Making Test (TMT) – Evaluates visual attention and task switching
• Symbol Digit Modalities Test (SDMT) – Assesses cognitive functioning
• Rey Auditory-Verbal Learning Test (RAVLT) – Assesses verbal learning and memory
• Korean version of Perceived Deficits Questionnaire-Depression – Measures subjective cognitive complaints in depression
• Motor Evoked Potential (MEP) parameters – Measures brain electrical activity related to motor function

The results of these ongoing clinical trials will provide more evidence about the effectiveness of choline alfoscerate for different cognitive conditions^[1][2][3][4].

Side Effects and Safety

The clinical trials are assessing the safety and tolerability of choline alfoscerate as part of their secondary outcomes^[2][3]. While specific side effects are not detailed in the trial summaries, the studies are monitoring for adverse events.

In general, medications that affect the cholinergic system may cause side effects such as gastrointestinal issues (nausea, vomiting, diarrhea), increased sweating, and changes in heart rate or blood pressure. However, the specific side effect profile of choline alfoscerate should be discussed with a healthcare provider.

The double-blind, placebo-controlled design of these studies will help determine whether any side effects are specifically related to choline alfoscerate or might occur with equal frequency in patients taking a placebo^[1][2][3].

Table of Contents

• What is Brexpiprazole Fumarate?
• What Conditions Does Brexpiprazole Fumarate Treat?
• Dosage Forms and Administration
• Ongoing Research and Clinical Trials
• Effects of Food on Brexpiprazole
• Long-term Use and Safety
• Efficacy Studies in Acute Schizophrenia

What is Brexpiprazole Fumarate?

Brexpiprazole Fumarate, also known as OPC-34712FUM, is a medication being studied for the treatment of schizophrenia. Schizophrenia is a serious mental health condition that affects a person’s thoughts, feelings, and behaviors. This medication is part of a new generation of antipsychotic drugs designed to help manage the symptoms of schizophrenia more effectively.^[1][2][3]

What Conditions Does Brexpiprazole Fumarate Treat?

Based on the clinical trials information provided, Brexpiprazole Fumarate is primarily being studied for the treatment of:

• Schizophrenia: This is a chronic mental disorder that affects how a person thinks, feels, and behaves. People with schizophrenia may experience hallucinations, delusions, and disorganized thinking.^[1][2]
• Acute Schizophrenia: This refers to a phase of schizophrenia where symptoms are severe and may require immediate treatment.^[3]

The medication is being tested to see how well it can manage both long-term symptoms and acute episodes of schizophrenia.

Dosage Forms and Administration

Brexpiprazole Fumarate is being developed as a once-weekly (QW) formulation. This means that patients would only need to take the medication once a week, which could be more convenient than daily medications. The current dosage forms being studied include:

• 24 mg tablets
• 48 mg weekly dose (two 24 mg tablets taken together)

In some studies, patients start with a lower dose of 24 mg (one tablet) and then increase to 48 mg (two tablets) after the first week.^[1][2][3]

Ongoing Research and Clinical Trials

Several clinical trials are currently underway to study different aspects of Brexpiprazole Fumarate:

1. Food Effect Study: This trial is investigating how food affects the way the body processes Brexpiprazole. Researchers are comparing how the medication works when taken with food versus when taken on an empty stomach.^[1]
2. Long-term Administration Trial: This study is looking at the safety and effectiveness of Brexpiprazole when used for an extended period (52 weeks) in patients with schizophrenia.^[2]
3. Acute Schizophrenia Trial: This trial is testing how well Brexpiprazole works in treating acute symptoms of schizophrenia compared to a placebo (a substance with no active medication).^[3]

These studies will help researchers understand how best to use Brexpiprazole in treating schizophrenia.

Effects of Food on Brexpiprazole

One of the ongoing studies is specifically looking at how food affects the way Brexpiprazole works in the body. This is important because some medications can work differently when taken with or without food. The study is measuring:

• Maximum plasma concentration (Cmax): This is the highest level of the drug in the blood after taking a dose.
• Area Under Curve (AUC): This measures the total exposure to the drug over time.

By comparing these measurements when the drug is taken with food versus on an empty stomach, researchers can determine if patients should take Brexpiprazole with meals or not.^[1]

Long-term Use and Safety

A 52-week study is being conducted to assess the long-term effects of Brexpiprazole. This trial aims to:

• Confirm the tolerability of the medication when used for an extended period
• Assess the safety of long-term use
• Evaluate the effectiveness of Brexpiprazole in managing schizophrenia symptoms over time

The primary measure in this study is the frequency of Adverse Events, which are any unfavorable and unintended signs, symptoms, or diseases that occur during the study period. This information will help doctors understand the potential risks and benefits of long-term Brexpiprazole use.^[2]

Efficacy Studies in Acute Schizophrenia

A specific trial is focusing on how well Brexpiprazole works in treating acute schizophrenia. This study:

• Compares Brexpiprazole to a placebo
• Lasts for 7 weeks
• Measures changes in schizophrenia symptoms using the Positive and Negative Syndrome Scale (PANSS)

The PANSS is a standardized tool used to measure the severity of symptoms in schizophrenia. By comparing the change in PANSS scores between patients taking Brexpiprazole and those taking a placebo, researchers can determine how effective the medication is in treating acute schizophrenia symptoms.^[3]

The purpose of the study is to determine the drug’s bioavailability, meaning how much of the medication reaches the bloodstream when taken as a pill compared with the tiny IV dose. By comparing the two administrations, researchers can learn how the body absorbs and processes the medication.

Volunteers will first swallow the tablet, then, after a short waiting period, receive the IV microdose. Blood samples will be collected at several time points over the next few hours to measure the amount of drug in the blood. The entire procedure is completed within a single visit, and no additional treatments are given.

Table of Contents

• Trial overview
• Who is being studied
• What is being measured
• Trial design and treatment groups
• Why this study matters

Trial overview

The available clinical trial for GXV813 is a Phase 2 interventional study called STAR-1.^[1] It is authorised and includes 142 participants.^[1]

The study is designed to assess the safety, tolerability, and treatment response of GXV813 in people with schizophrenia.^[1] The trial compares GXV813 with placebo to see whether the study drug improves symptoms.^[1]

Who is being studied

This study focuses on hospitalized adults with schizophrenia who are having an acute episode.^[1] The trial summary says the participants are adult inpatients diagnosed according to DSM-5 criteria.^[1]

In simple terms, this means the study is looking at people who are currently in the hospital and whose symptoms are active enough to need close care.^[1]

What is being measured

The main endpoint is the change from baseline in PANSS total score at 6 weeks.^[1] Baseline means the starting point before treatment begins.^[1]

PANSS stands for Positive and Negative Symptom Scale, which is a rating tool used to measure schizophrenia symptoms.^[1] A change in this score helps researchers see whether symptoms improve, worsen, or stay the same over time.^[1]

Trial design and treatment groups

The study is interventional, which means researchers assign the treatment rather than just observing what happens.^[1] The interventions listed are GXV813 given orally and placebo in hard gelatin capsule form.^[1]

Placebo is a comparison treatment that does not contain the active study drug.^[1] Using placebo helps researchers judge whether any symptom change is due to GXV813 rather than chance or other factors.^[1]

Why this study matters

Schizophrenia can affect both positive symptoms, such as hallucinations or delusions, and negative symptoms, such as low motivation or reduced speech.^[1] This trial is important because it focuses on both types of symptoms in a hospital setting where people may need close monitoring.^[1]

Because the study is in Phase 2, it is part of the process of learning whether GXV813 may help people with schizophrenia and how it performs in a larger patient group.^[1]

Table of contents

• Trial overview
• Who the trial is for
• What is being studied
• Trial phase and design
• Outcomes being measured
• Treatments in the study
• Patient-focused summary

Trial overview

The available clinical trial is an interventional study called the PREDICT clinical trial, and it is authorised.^[1] It studies depressive disorder and looks at whether a pre-emptive pharmacogenetic strategy can improve the choice of antidepressant treatment after a previous treatment has failed.^[1]

The trial includes 240 participants and is in Phase 3.^[1] Its brief summary says the study compares a personalized medicine approach with standard clinical practice in people who are starting a new therapy after treatment failure.^[1]

Who the trial is for

This trial is for patients with depressive disorder who need a new antidepressant after their prior therapy did not work well enough.^[1] The source data does not give more detailed entry rules such as age limits or exact lab requirements.^[1]

• Target population: people with depressive disorder.^[1]

• Treatment situation: starting a new antidepressant after prior treatment failure.^[1]

• Study setting: patients are being evaluated in a real treatment decision context, not just for one fixed drug choice.^[1]

What is being studied

The main question is whether a pre-emptive pharmacogenetic strategy can help choose antidepressants better than usual care.^[1] Pre-emptive means the testing is done before the treatment decision is made, and pharmacogenetic means the study uses gene-related information to guide medicine selection.^[1]

The study also uses demographic, clinical, and concomitant medication data when making treatment decisions.^[1] Concomitant medication means other medicines a patient is already taking at the same time.^[1]

Although the trial is about treatment selection rather than one single drug, TRIMIPRAMINE MALEATE is included among the treatment options listed in the study data.^[1]

Trial phase and design

This is a Phase 3 clinical trial.^[1] Phase 3 trials usually test how well a strategy works in a larger group and help compare it with routine care.^[1]

The study is interventional, which means researchers actively assign or guide the treatment approach being tested.^[1] In this case, the intervention is the personalized selection strategy, not only a single medicine.^[1]

Outcomes being measured

The main outcome is symptom remission, meaning the depression symptoms improve a lot or may no longer be present.^[1] The trial measures this by looking at changes in depression severity scores after the new antidepressant treatment begins.^[1]

• PHQ-9: a patient questionnaire used to measure depression severity.^[1]

• MADRS: a clinician-rated scale used to measure how severe depression symptoms are.^[1]

The outcome is assessed after initiation of the new antidepressant treatment following failure of the prior therapy at study entry.^[1]

Treatments in the study

The intervention list includes many antidepressants and related medicines, such as escitalopram, duloxetine, fluvoxamine, sertraline, desvenlafaxine, fluoxetine, vortioxetine, venlafaxine, amitriptyline hydrochloride, citalopram, bupropion, mirtazapine, valproxan, quetiapine, and TRIMIPRAMINE MALEATE.^[1]

These medicines are part of the treatment selection process being compared in the trial, so the study is focused on choosing the right antidepressant strategy rather than testing only one product by itself.^[1]

• Antidepressant choices: the trial includes several medicines so researchers can compare how well the selection strategy works in practice.^[1]

• Personalized selection: the study uses gene-related and clinical information to help decide which treatment may work best.^[1]

Patient-focused summary

For patients, this trial is about finding a better way to choose antidepressant treatment after one treatment has not helped enough.^[1] The study asks whether adding genetic testing and other patient information can improve the chance of remission compared with usual care.^[1]

The source data does not report results yet, so the main focus is on the study goal, the patient group, and the outcomes being measured.^[1]

Table of Contents

• Trial overview
• Who can participate
• Study design and treatment groups
• What is being measured
• Trial status and size

Trial overview

One clinical trial is studying NBI-1117570 in adults with schizophrenia who need inpatient hospitalization.^[1] The trial is designed to see whether the study drug can improve behavioral and psychological symptoms of schizophrenia compared with placebo.^[1]

This is an interventional study, which means researchers give a study treatment and then measure the results.^[1] The trial is in Phase 2, so it is focused on learning more about how well the treatment may work while still collecting study information on safety and effects.^[1]

Who can participate

The trial is for inpatient adults with schizophrenia.^[1] Inpatient means the person is staying in a hospital setting for treatment, not just coming for a short visit.^[1]

The source data does not give more detail about other entry rules, such as exact age limits, symptom levels, or past treatment history.^[1]

Study design and treatment groups

The trial compares NBI-1117570 with placebo.^[1] A placebo is a look-alike treatment that does not contain the active study drug, and it helps researchers compare outcomes in a fair way.^[1]

The intervention list shows oral use for NBI-1117570 and a placebo for NBI-1117570.^[1] The study data do not provide more detail about the schedule of treatment or how long participants are followed.^[1]

What is being measured

The main outcome is the change from baseline in the Positive and Negative Syndrome Scale, or PANSS, total score.^[1] Baseline means the starting measurement before treatment begins.^[1]

PANSS is a score used to measure how severe schizophrenia symptoms are.^[1] In simple terms, the researchers are checking whether symptoms improve after treatment and whether the change is greater than with placebo.^[1]

Trial status and size

The trial status is Authorised, which means it has permission to start.^[1] The planned enrollment is 169 participants.^[1]

Because only one trial is listed in the source data, the current research picture for NBI-1117570 is limited to this Phase 2 study in hospitalized adults with schizophrenia.^[1]